Crinetics Pharmaceuticals Inc Revenue Growth Rates (CRNX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Crinetics Pharmaceuticals Inc   (NASDAQ: CRNX)
 

CRNX's Revenue Growth by Quarter and Year

Crinetics Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CRNX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 25.12
1st Quarter March 10.73
FY 35.85

CRNXs Annual Revenue
Crinetics Pharmaceuticals Inc 's Revenue in the fiscal year 2025 $ 7.70 millions
Crinetics Pharmaceuticals Inc 's Revenue in the fiscal year 2024 $ 1.04 millions
Crinetics Pharmaceuticals Inc 's Revenue in the fiscal year 2023 $ 4.01 millions
Crinetics Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 4.74 millions
Crinetics Pharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 1.08 millions




CRNX Revenue second quarter 2026 Y/Y Growth Comment
Crinetics Pharmaceuticals Inc achieved in the second quarter 2026, above Company average Revenue surge of 2338.64% year on year, to $ 25.12 millions.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 22 other companies have achieved higher Revenue growth. While Crinetics Pharmaceuticals Inc ' s Revenue doubling of 2338.64% ranks overall at the positon no. 127 in the second quarter 2026.


CRNX Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - - - -
3rd Quarter September - - - -23.91 %
2nd Quarter June 2338.64 % 157.5 % -59.6 % 125 %
1st Quarter March 2880.56 % -43.75 % -76.12 % -14.38 %
FY   - 639.42 % -74.13 % -

Financial Statements
Crinetics Pharmaceuticals Inc 's second quarter 2026 Revenue $ 25.12 millions CRNX's Income Statement
Crinetics Pharmaceuticals Inc 's second quarter 2025 Revenue $ 1.03 millions Quarterly CRNX's Income Statement


CRNX Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 4300 % - -
3rd Quarter September - -86.41 % - -64.65 %
2nd Quarter June 134.09 % 186.11 % -37.5 % -63.06 %
1st Quarter March 74.19 % - - 277.46 %
FY (Year on Year)   - 639.42 % -74.13 % -


Back to CRNX Growth rate Comparisons >> Back to CRNX Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #23
Healthcare Sector #39
Overall #127

Revenue Y/Y Growth Statistics
High Average Low
18.73 % 2.52 % -7.52 %
(Dec 31 2018)   (Sep 30 2023)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #23
Healthcare Sector #39
Overall #127
Revenue Y/Y Growth Statistics
High Average Low
18.73 % 2.52 % -7.52 %
(Dec 31 2018)   (Sep 30 2023)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Crinetics Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
4208.39 % 221.89 % -100 %
(Dec 31 2025)  


CRNX's II. Quarter Q/Q Revenue Comment
Crinetics Pharmaceuticals Inc achieved in the II. Quarter 2026 below company average Revenue doubling of 134.09% quarter on quarter, to $ 25.12 millions.

Within Major Pharmaceutical Preparations industry 22 other companies have achieved higher Revenue quarter on quarter growth. While Crinetics Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 113.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #23
Healthcare Sector #38
Overall #113
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #23
Healthcare Sector #38
Overall #113
Revenue Q/Q Growth Statistics
High Average Low
4208.39 % 221.89 % -100 %
(Dec 31 2025)  


CRNX's II. Quarter Q/Q Revenue Comment
Crinetics Pharmaceuticals Inc achieved in the II. Quarter 2026 below company average Revenue doubling of 134.09% quarter on quarter, to $ 25.12 millions.

Within Major Pharmaceutical Preparations industry 22 other companies have achieved higher Revenue quarter on quarter growth. While Crinetics Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 113.


Crinetics Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 42.16 $ 18.07 $ 7.70 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) 133.31 % 134.78 % - - -
Seq. Revenue Growth (TTM) Overall Ranking # 127 # 96 # 0 # 0 # 0


Cumulative Revenue growth Comment
Crinetics Pharmaceuticals Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 2338.64% year on year, to $ 42 millions if the fiscal year would have ended in Jun 30 2026.
Crinetics Pharmaceuticals Inc 's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Mar 31 2026. And, Crinetics Pharmaceuticals Inc realized the fastest Revenue growth, in Major Pharmaceutical Preparations industry.
But from twelve months ended Mar 31 2026 rise was beneth at 133.31 % from $18.07 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at 2.52%.

Crinetics Pharmaceuticals Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 23
Sector # 39
S&P 500 # 127
Cumulative Revenue growth Comment
Crinetics Pharmaceuticals Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 2338.64% year on year, to $ 42 millions if the fiscal year would have ended in Jun 30 2026.
Crinetics Pharmaceuticals Inc 's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Mar 31 2026. And, Crinetics Pharmaceuticals Inc realized the fastest Revenue growth, in Major Pharmaceutical Preparations industry.
But from twelve months ended Mar 31 2026 rise was beneth at 133.31 % from $18.07 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at 2.52%.
The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 133.31 % increase from $18.07 millions in the period from Mar 31 2026 to Jun 30 2025.

Crinetics Pharmaceuticals Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 23
Sector # 39
S&P 500 # 127




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CRNX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue doubling for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Hcw Biologics Inc 3,828.21%$ 3,828.214 millions
Protagonist Therapeutics inc 3,749.17%$ 3,749.171 millions
Aligos Therapeutics Inc 2,778.55%$ 2,778.549 millions
Crinetics Pharmaceuticals Inc 2,336.28%$ 2,336.275 millions
Tao Synergies Inc 2,136.90%$ 2,136.901 millions
Liquidia Corporation1,842.73%$ 1,842.729 millions
Verastem Inc 1,775.43%$ 1,775.433 millions
EBR Systems, Inc.1,453.92%$ 1,453.919 millions
Safe Pro Group Inc 1,336.15%$ 1,336.152 millions


About Crinetics Pharmaceuticals Inc Revenue Growth Rates (CRNX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Crinetics Pharmaceuticals Inc (CIK 1658247).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001658247-26-000053
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Crinetics Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.